<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:6pt Arial, sans-serif; }
 .font1 { font:7pt Arial, sans-serif; }
 .font2 { font:10pt Arial, sans-serif; }
 .font3 { font:12pt Arial, sans-serif; }
 .font4 { font:17pt Arial, sans-serif; }
 .font5 { font:10pt Times New Roman, serif; }
 .font6 { font:15pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font6">JPMorgan</span></p>
<p><span class="font1" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">26 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Katherine Lei</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8552</span></p>
<p><a href="mailto:katherine.lei@jpmorgan.com"><span class="font0" style="font-weight:bold;">katherine.lei@jpmorgan.com</span></a></p>
<p><a name="bookmark0"></a><span class="font4"><a name="bookmark1"></a>Investment Thesis, Valuation and Risks</span></p>
<p><span class="font3" style="font-weight:bold;">China Minsheng Banking - H </span><span class="font2" style="font-style:italic;">(Underweight; Price Target: HKS7.50)</span></p>
<p><a name="bookmark2"></a><span class="font5" style="font-weight:bold;"><a name="bookmark3"></a>Investment Thesis</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Recent regulatoiy action against MRAM, could lead to downside on fee income. MRAM is a subsidiary of Minsheng’s asset management company MRFM. The AUM of MRAM has increased fivefold in two years, and agency and custodian fees account for -20% of Minsheng's revenue.</span></p></li>
<li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Rising pressure on liquidity and capital curtail profit growth: Minsheng’s LCR is the lowest among peers in 2015. Its core capital ratio is one of the lowest among its peers as well. Minsheng is unfavorably positioned under the new MPA regulatory framework, which regulators may penalize banks in RRR interest rate for weak capital and liquidity positon. New business expansion may also be negatively impacted.</span></p></li>
<li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Minsheng has one of the lowest Tier-1 ratios among H-share banks. This may come under further regulatoiy pressure as Basel III is phased in each year.</span></p></li>
<li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Off-balance sheet exposure increasing: WMP AUM went up substantially.</span></p></li></ul>
<p><a name="bookmark4"></a><span class="font5" style="font-weight:bold;"><a name="bookmark5"></a>Valuation</span></p>
<p><span class="font5">Our Dec-17 price target of HK$7.5 is based on DDM, using a cost of equity of 14.7%, normalised ROE of 11.5%, and terminal date of 31 December 2018.</span></p>
<p><span class="font5" style="font-weight:bold;">Risks to Rating and Price Target</span></p>
<ul style="list-style:none;"><li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Upside risk risks to our rating and price target: Minsheng is a high-beta stock, so it tends to outperform peers when growth risk subsides. We believe that if inflation risk is lower than expected and there is a new round of quantitative easing, Minsheng could continue to rally despite weaker fundamentals.</span></p></li>
<li>
<p><span class="font5">• &nbsp;&nbsp;&nbsp;Further downside risks: There are risks that Minsheng may need to make provisions on some of the assets in its asset management subsidiary; Minsheng’s asset quality may continue to deteriorate, especially for its off-balance sheet shadow banking exposure.</span></p></li></ul>
<p><span class="font0" style="font-weight:bold;">2</span></p>
</body>
</html>